Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. announced that The first patient in the confirmatory clinical trial of aminolevulinic acid hydrochloride powder for oral
solution (the "Drug") for intraoperative visualisation of glioma (WHO grade III or IV) (the "Study") has recently been successfully enrolled in the Study.